ArticleNatural products and bioprospecting2026
Isolation, structural characterization of oligosaccharide AMO-1 from Avicennia marina fruit and its anti-osteoporotic effects via PI3K/AKT/HIF‑1α signaling pathway activation.
Article in Natural products and bioprospecting, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Avicennia marina (Forssk.) Vierh. is an important mangrove plant with high nutritional and medicinal values, featuring saccharides as its primary bioactive compounds. In this study, we successfully isolated a neutral tetrasaccharide (AMO-1) from the fruits of A. marina. Through monosaccharide composition, methylation, UPLC-ESI-MS/MS, and NMR analyses, we revealed that the structure of AMO-1 was α-D-Galp-(1 → 6)-α-D-Galp-(1 → 6)-α-D-Glcp-(1 → 2)-β-D-Fruf. Subsequently, we investigated the anti-osteoporosis (anti-OP) efficacy and underlying mechanisms of AMO-1. Our findings demonstrated that AMO-1 promoted the differentiation and mineralization of MC3T3-E1 cells. Furthermore, AMO-1 increased trabecular bone density and restored its reticular structure in dexamethasone-induced OP mice. Additionally, AMO-1 upregulated the expression levels of osteogenic factors and elevated serum levels of osteocalcin and PINP. Mechanistically, AMO-1 promoted osteogenesis through activation of the PI3K/AKT/HIF-1α signaling pathway, thus exerting anti-OP effects. Overall, these findings indicate that AMO-1 is a promising functional food ingredient with therapeutic potential for the prevention and management of OP.
Indexed as
Identifiers
42911466What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.